Articles On Opthea (ASX:OPT)

I think a little exposure to the small side of the market can be a good thing for a portfolio. This is because even blue chip companies such as Ramsay Health Care Limited (ASX: RHC) and TPG Telecom Ltd (ASX: TPM) were small caps at one sta...

The Opthea Ltd (ASX: OPT) share price has been one of the best performers on the All Ordinaries in 2019. Since the start of the year the shares of the developer of novel biologic therapies for the treatment of eye diseases have gained a ma...

The BWX Ltd (ASX: BWX) share price is pushing higher again on Tuesday. In afternoon trade the personal care products company’s shares are up 1.5% to $4.48. This latest gain means that BWX’s shares are now up a remarkable 183% in 2019. This...

Paradigm Biopharmaceuticals Ltd (ASX: PAR) shares are up from 99 cents on New Year’s day 2019 to $3.49 today and even hit as high as $4.12 last November. What does Paradigm do? With its shares up 250% in less than a year you’d think Paradi...

I think the ASX is home to a good number of small cap shares that have the potential to grow notably larger in the future. While history shows that not all small caps will ultimately deliver on their potential, I think many of these shares...

Opthea Limited (ASX: OPT) has completed the private placement announced recently on 2 December 2019. Opthea has raised $50 million through the issue of approximately 18.9 million fully paid ordinary shares at an issue price of $2.65 per New...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

The process of drug development is launching a new pharmaceutical compound to the market after the lead compound identification through drug discovery. The drug development process includes drug discovery and development, preclinical &...

Australian biotechnology company Opthea (ASX:OPT) has announced it has received commitments from sophisticated and institutional investors to raise $50 million via a private placement.

In afternoon trade the S&P/ASX 200 index is on course to start the week on a high. At the time of writing the benchmark index is up 0.6% to 6,885.3 points. Four shares that are climbing more than most on Monday are listed below. Here’s...

Opthea Limited (ASX: OPT) has received commitments from sophisticated and institutional investors in Australia and the UK to raise $50 million through a private placement. The funds raised through the placement would support in the late-st...

The Opthea Ltd (ASX: OPT) share price is on the move on Monday after announcing an institutional placement. The clinical-stage biopharmaceutical company’s shares are up 4.5% to $2.86 at the time of writing. What did Opthea announce? This m...

02 Dec 2019 - Biopharmaceutical company Opthea (ASX:OPT) today announced that the company has received commitments from sophisticated and institutional investors in Australia and t…

The participants in the health care industry are always in the process of developing innovative treatments/therapies and expanding their business by providing new or existing treatments in a wider area, or geography.  In the health care sec...

Australia’s health care industry is one of the fastest growing industries in the country that is making substantial progress driven by new technological advancements. The country’s government is injecting billions of dollars into modernisin...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

In recent years, Australia’s health care industry has remarkably grown in terms of size and reputation for its world-leading technology, advanced R&D, innovation, leading scientists and health care professionals. Australia is one of the...

The Next Science Ltd (ASX: NXS) share price has slipped 5% to $2.52 today but investors shouldn’t be disheartened as the stock is still up 150% from its April 2019 $1 per share initial public offer price.  For the quarter ending September...

The healthcare sector can be viewed with high scepticism as it’s difficult to invest without being a subject matter expert. But with this high barrier to entry comes a huge opportunity to capture alpha. To make it easier for you, I’ve put...

The Novita Healthcare Ltd (ASX: NHL) share price is now up around 4.5x or 350% since last week. That’s not a typo either as the early learning childhood technology business reported that its TALi Detect platform could be delivered via the...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has gone gangbusters in 2019 as wild investor excitement mounts over its Zilosul drug’s commercial potential. The biotech now has a market value around $516 million despite posting...

Botanix Pharmaceuticals’ (ASX:BOT) shares have halved after its anti-acne drug failed its clinical trial. If you read most of the company’s announcement and you’d would have thought the 368 patient trial was a success. Its drug, BTX 1303, w...

What are Small-Cap Stocks? Small-cap stocks are the stocks, which have smaller market capitalisation or otherwise said as a small-sized company. Although small-cap stocks may not be on the priority of an investor as the market’s large-cap s...

It looks set to be a disappointing end to the week for the S&P/ASX 200 index. In afternoon trade the benchmark index is trading 0.6% lower at 6,643.1 points. Four shares that have not let that hold them back are listed below. Here’s wh...

The market may have dropped lower today, but that hasn’t stopped the Opthea Ltd (ASX: OPT) share price from racing higher. In morning trade the shares of the developer of novel biologic therapies for the treatment of eye diseases are up ov...

It’s paramount to hold equities that can capture alpha. By making bets on growth companies, this gives you a higher chance of boosting portfolio returns to complement your blue-chips. Here are 3 ASX companies that have grown exponentially...

Strong gains among selected life science shares is fuelling optimism the sector may have further to run. Life sciences stocks are involved in things like biotech, genetics, pharmaceuticals and medical devices. In a low growth earnings envir...

With the prospect of a global recession heightening, it’s important to have stocks in your portfolio with a strong likelihood of outperforming. Here are three ASX companies with defensible positions that are my picks for the long-haul. Ari...

This year has been a positive one for ASX small caps. According to Bloomberg, the average small cap has gained just under 5 per cent and some of the major sectors have seen double digit percentage gains. One example is the health sector whi...

Australian biopharmaceutical company Opthea (ASX:OPT) has announced the presentation of additional data from the recently completed 366 patient Phase 2b randomised controlled wet AMD study of OPT-302 with Novartis' PBS-listed LUCENT...

One of the best performers on the All Ordinaries index this year has been the Opthea Ltd (ASX: OPT) share price. Since the start of the year the shares of the developer of novel biologic therapies for the treatment of eye diseases have ral...

While these last few weeks have been filled with investor uncertainty, there have been clear outperformers. Recently, these 3 ASX healthcare shares have been popping up on my radar after posting strong FY19 results. If you’re looking to su...

The FDA’s decision on Clinvel Pharmaceuticals’ (ASX: CUV) SCENESSE treatment for erythropoietic protoporphyria capped off a stellar ride that’s lasted several years. Erthropoietic protoporphyria (EPP) is a rare skin order causing severe rea...

The Polynovo Ltd (ASX: PNV) share price is up 7% to $2.43 this lunchtime despite the biotech not releasing any specific news to the market. On September 23 the little-known surgical material business joined the S&P/ ASX200 (ASX: XJO) in...

The Orthocell Ltd (ASX: OCC) share price is up 25% to 50 cents today after the regenerative medicine researcher announced trial results showed its medical device CelGro® had helped quadriplegics regain arm and hand functions.  CelGro® is r...

Health care, being the dynamic sector, keep investors on their toes before injecting their funds. Vigilance to information is an important criterion that allows investors and market enthusiasts to capitalise money in the stocks. Variables p...

Analysts and CEOs of  companies targeting vision loss say there’s market opportunities above US$10 billion ($14.89 billion) for the taking. We aren’t talking about the entire vision loss market here. That’s $US10 billion worth of treatments...

According to Opthea CEO and managing director, Dr Megan Baldwin, “This R&D tax incentive credit of A$14.6 million increases the company’s cash balances to over A$30 million and will contribute to the execution and delivery of ou...

Mesoblast limited (ASX: MSB) shares are locked in a trading halt today with the regenerative medicine business reportedly seeking to raise another $75 million according to news reports in the Australian Financial Review. Mesoblast has often...

Now that reporting season is over, with the deadline for audited accounts passing yesterday, Stockhead recaps the ASX small caps that have won the attention of the most brokers. The most analysed small cap is lithium explorer Galaxy Resourc...

There’s an old saying — ‘an apple a day keeps the doctor away’. But these days, its biotechs — not apples — that are working hard to keep patients out of a congested medical system. Rhythm Biosciences (ASX: RHY) main asset is Colostat – a b...

This week’s recap of substantial holder transactions among ASX small caps covers everything from fund managers investing client cash to shares being handed down from one generation to the next. Substantial shareholders are shareholders hold...

The AVITA Medical Ltd (ASX: AVH) share price has been on fire again on Wednesday and has carved out another sizeable gain. In afternoon trade the regenerative medicine company’s shares are up 12.5% to 58.5 cents. This latest gain means tha...

A lot of retail share market traders like to pile into whatever’s hot or going up fast in the small-cap sector as they’re more interested in price action than the merits of the underlying business. In turn the hot money can amplify the sha...

Amidst global trade concerns and lower interest rate environment, investors are turning their investments into equity market. With Australia’s equity market offering decent returns, one sector that has garnered significant investor traction...

The S&P/ASX 200 index is on course to end its positive run with a disappointing decline on Tuesday. In afternoon trade the benchmark index is down 0.6% to 6,609.6 points. Four shares that have fallen more than most today are listed bel...

The share price of the Australian company developing a new eye therapy has quadrupled in recent weeks with its market capitalisation topping $900 million.

Short & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorted. Stocks that are shorted have investors betting that they fall. Shorting works by “selling” stocks you do not actually own in the hope of...

It’s not every day that a former doctoral student takes their thesis and turns it into a $1 billion venture, but that is just what Megan Baldwin has done at biotech outfit Opthea. Biotechnology is a crowded corner of the ASX which is filled...

The Opthea Ltd (ASX: OPT) share price is up 2.4% to $3.83 today after the eye disease treatment biotech updated investors on progress over its Phase 2b clinical trial into its OPT-302 with ranibizumab (Lucentis®) treatment compared to rani...